Gary Bellinger
Lab Manager - Politi Lab; Lab Manager, Research Associate II-MS, MEDCCC Research Affairs/YCC
Research & Publications
Biography
News
Coauthors
Selected Publications
- Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinomaDavidson S, Schmidt D, Heyman J, O'Brien J, Liu A, Israelsen W, Dayton T, Sehgal R, Bronson R, Freinkman E, Mak H, Fanelli G, Malstrom S, Bellinger G, Carracedo A, Pandolfi P, Courtney K, Jha A, DePinho R, Horner J, Thomas C, Cantley L, Loda M, Heiden M. Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma. Cancer Research 2022, 82: 2403-2416. PMID: 35584006, PMCID: PMC9256808, DOI: 10.1158/0008-5472.can-21-2352.
- Abstract LB-333: PARP-1 supports HPV infection and HPV-associated head and neck cancerPan C, Biktasova A, Hajek M, Sewell A, Sathe T, Bellinger G, Yarbrough W, Issaeva N. Abstract LB-333: PARP-1 supports HPV infection and HPV-associated head and neck cancer. Cancer Research 2018, 78: lb-333-lb-333. DOI: 10.1158/1538-7445.am2018-lb-333.
- Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck CancerBiktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.
- Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent mannerWamsley JJ, Gary C, Biktasova A, Hajek M, Bellinger G, Virk R, Issaeva N, Yarbrough WG. Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner. Oncogenesis 2017, 6: e314-e314. PMID: 28394357, PMCID: PMC5520489, DOI: 10.1038/oncsis.2017.12.
- Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletionJuvekar A, Hu H, Yadegarynia S, Lyssiotis C, Ullas S, Lien E, Bellinger G, Son J, Hok R, Seth P, Daly M, Kim B, Scully R, Asara J, Cantley L, Wulf G. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: e4338-e4347. PMID: 27402769, PMCID: PMC4968752, DOI: 10.1073/pnas.1522223113.
- Selective antitumor activity of roscovitine in head and neck cancerGary C, Hajek M, Biktasova A, Bellinger G, Yarbrough WG, Issaeva N. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget 2016, 7: 38598-38611. PMID: 27233076, PMCID: PMC5122414, DOI: 10.18632/oncotarget.9560.
- Pyruvate Kinase Isoform Expression Alters Nucleotide Synthesis to Impact Cell ProliferationLunt S, Muralidhar V, Hosios A, Israelsen W, Gui D, Newhouse L, Ogrodzinski M, Hecht V, Xu K, Acevedo P, Hollern D, Bellinger G, Dayton T, Christen S, Elia I, Dinh A, Stephanopoulos G, Manalis S, Yaffe M, Andrechek E, Fendt S, Heiden M. Pyruvate Kinase Isoform Expression Alters Nucleotide Synthesis to Impact Cell Proliferation. Molecular Cell 2014, 57: 95-107. PMID: 25482511, PMCID: PMC4289430, DOI: 10.1016/j.molcel.2014.10.027.
- Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null TumorsEmerling B, Hurov J, Poulogiannis G, Tsukazawa K, Choo-Wing R, Wulf G, Bell E, Shim H, Lamia K, Rameh L, Bellinger G, Sasaki A, Asara J, Yuan X, Bullock A, DeNicola G, Song J, Brown V, Signoretti S, Cantley L. Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. Cell 2013, 155: 844-857. PMID: 24209622, PMCID: PMC4070383, DOI: 10.1016/j.cell.2013.09.057.
- PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor CellsIsraelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Heiden M. PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. Cell 2013, 155: 397-409. PMID: 24120138, PMCID: PMC3850755, DOI: 10.1016/j.cell.2013.09.025.
- Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine MetabolismFendt S, Bell E, Keibler M, Davidson S, Wirth G, Fiske B, Mayers J, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin M, Cantley L, Guarente L, Blenis J, Pollak M, Olumi A, Heiden M, Stephanopoulos G. Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine Metabolism. Cancer Research 2013, 73: 4429-4438. PMID: 23687346, PMCID: PMC3930683, DOI: 10.1158/0008-5472.can-13-0080.
- Abstract 4588: Identification of CDCP1 as a HIF-2α target gene involved in the regulation of cancer cell migration and metastasis.Emerling B, Benes C, Bell E, Poulogiannis G, Courtney K, Lui H, Choo-Wing R, Bellinger G, Soltoff S, Cantley L. Abstract 4588: Identification of CDCP1 as a HIF-2α target gene involved in the regulation of cancer cell migration and metastasis. Cancer Research 2013, 73: 4588-4588. DOI: 10.1158/1538-7445.am2013-4588.
- AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen C, Wen J, Asara J, McGraw T, Kahn B, Cantley L. AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1. Molecular Cell 2013, 49: 1167-1175. PMID: 23453806, PMCID: PMC3615143, DOI: 10.1016/j.molcel.2013.01.035.
- Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patientsEmerling B, Benes C, Poulogiannis G, Bell E, Courtney K, Liu H, Choo-Wing R, Bellinger G, Tsukazawa K, Brown V, Signoretti S, Soltoff S, Cantley L. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 3483-3488. PMID: 23378636, PMCID: PMC3587206, DOI: 10.1073/pnas.1222435110.
- Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancerPatnaik A, Courtney K, Robichaud K, Bellinger G, Nardella C, Signoretti S, Wooster R, Pandolfi P, Cantley L. Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer. Cancer Research 2012, 72: lb-365-lb-365. DOI: 10.1158/1538-7445.am2012-lb-365.
- Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant ResponsesAnastasiou D, Poulogiannis G, Asara J, Boxer M, Jiang J, Shen M, Bellinger G, Sasaki A, Locasale J, Auld D, Thomas C, Heiden M, Cantley L. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. Science 2011, 334: 1278-1283. PMID: 22052977, PMCID: PMC3471535, DOI: 10.1126/science.1211485.
- Abstract LB-418: Targeting the PI3K/mTOR pathway in genetically engineered mouse models of prostate cancerPatnaik A, Courtney K, Bellinger G, Lunsford E, Robichaud K, Grant A, Lenkinski R, Pedrosa I, Signoretti S, Wooster R, Cantley L. Abstract LB-418: Targeting the PI3K/mTOR pathway in genetically engineered mouse models of prostate cancer. Cancer Research 2011, 71: lb-418-lb-418. DOI: 10.1158/1538-7445.am2011-lb-418.
- ErbB3 is required for ductal morphogenesis in the mouse mammary glandJackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, Stern DF. ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Research 2008, 10: r96. PMID: 19019207, PMCID: PMC2656891, DOI: 10.1186/bcr2198.
- Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, Gassmann M, Muller W, Kent Lloyd KC, Stern DF. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene 2006, 25: 5664-5672. PMID: 16652155, DOI: 10.1038/sj.onc.1209574.
- ErbB2 is required for ductal morphogenesis of the mammary glandJackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF. ErbB2 is required for ductal morphogenesis of the mammary gland. Proceedings Of The National Academy Of Sciences Of The United States Of America 2004, 101: 17138-17143. PMID: 15569931, PMCID: PMC535384, DOI: 10.1073/pnas.0407057101.